|
|
Article: New England Journal of Medicine Publishes First Clinical Study of Medication to Improve Wakefulness in Patients with Shift Work Sleep Disorder.
- Article from:
- PR Newswire
- Article date:
- August 3, 2005
|
Copyright informationCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Study Shows that PROVIGIL(R) (modafinil) Tablets [C-IV] Improves Patients' Ability to Remain Awake and Alert
FRAZER, Pa., Aug. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc. today announced that results of its pivotal Phase three study of PROVIGIL in patients with shift work sleep disorder (SWSD) has been published in this week's New England Journal of Medicine. In the first ever clinical study of SWSD, patients taking PROVIGIL showed improvements in their wakefulness, performance and level of attention.
"This study further clarifies the role excessive sleepiness plays in shift work sleep disorder, and the value of PROVIGIL in treating excessive sleepiness," said Dr. ...